Vancouver, BC – In a groundbreaking advance offering a new lifeline to young cancer patients, a pan-Canadian research team has pioneered a revolutionary method to rapidly identify personalized treatments for aggressive and rare pediatric cancers. The innovative approach combines the sophisticated analysis of tumour proteins with the unique ability to grow patient-derived tumours in chicken eggs, enabling an unprecedented speed and precision in therapeutic decision-making.
This pivotal development, spearheaded by researchers from the University of British Columbia (UBC) and BC Children’s Hospital Research Institute (BCCHR), marks the first instance in Canada where these two cutting-edge techniques have been synergistically applied to successfully identify and test a viable drug for a young patient’s tumour in real-time, directly impacting their treatment course. The success story, detailed today in the prestigious journal EMBO Molecular Medicine, underscores the transformative potential of proteomics – the comprehensive study of proteins – as a crucial complement to the established field of genomics in the demanding landscape of real-time cancer therapies.
The collaborative spirit driving this scientific triumph is embodied by PROFYLE (PRecision Oncology For Young peopLE), a flagship initiative of the Canadian pediatric cancer network ACCESS (Advancing Childhood Cancer Experience, Science and Survivorship). This formidable alliance brings together over 30 research and funding organizations and more than 100 investigators from across Canada, united by a singular mission: to dramatically improve cancer outcomes for children and young adults facing the most challenging diagnoses.
The Desperate Search for Solutions: A Patient’s Journey
The genesis of this breakthrough lies in the urgent need to find answers for patients who have exhausted conventional treatment options. The study by co-lead authors Dr. Georgina Barnabas, a postdoctoral researcher in Dr. Philipp Lange’s lab, and Tariq Bhat, a PhD student in Dr. James Lim’s lab, centered on an unnamed young patient grappling with a particularly aggressive and rare pediatric cancer. This formidable disease had stubbornly resisted standard chemotherapy regimens, leaving clinicians and family searching for an alternative path.
The initial conventional diagnostic approach relied heavily on genomics, the study of the tumour’s genetic makeup. While genomics has revolutionized cancer care by identifying specific mutations that can be targeted by drugs, in this patient’s case, it reached a frustrating impasse. After standard chemotherapy had failed and the tumour developed resistance to a drug initially selected based on genomic analysis, further genetic testing yielded no clear, actionable drug candidates. The molecular map of the tumour’s DNA, while detailed, did not point to a clear vulnerability that could be exploited therapeutically. This scenario, unfortunately, is not uncommon in pediatric oncology, where rare cancer types and the unique biological profiles of young patients often present diagnostic and therapeutic enigmas. The stakes were incredibly high, with the patient’s prognosis dimming as each conventional avenue closed.
Proteomics: Unlocking the Tumour’s Functional Blueprint
Facing a dead end with genomics, the research team made a strategic pivot, turning their attention to proteomics. While genes (DNA) provide the instructions for building proteins, proteins themselves are the functional workhorses of our cells. They carry out virtually all cellular processes, from catalyzing metabolic reactions to forming structural components and transmitting signals. Crucially, the vast majority of drugs exert their therapeutic effect by directly interacting with and altering the activity of proteins.
"With genomics alone, we couldn’t find a clear treatment option," explained Dr. Lange, who, alongside Dr. Lim and clinician Dr. Rebecca Deyell, are senior investigators with the Michael Cuccione Childhood Cancer Research Program at BCCHR. "But by looking at the tumour’s proteins, we found a critical metabolic weakness that we could target with an already approved drug."
This shift in focus proved to be a stroke of genius. The team hypothesized that even if the genetic code didn’t reveal a clear target, the activity of the proteins might expose a hidden vulnerability. Through meticulous proteomic analysis, they discovered that the patient’s tumour metabolism was heavily reliant on an enzyme called SHMT2 (Serine Hydroxymethyltransferase 2). This enzyme plays a crucial role in cellular growth and proliferation, particularly in rapidly dividing cancer cells, by supporting the synthesis of nucleotides and amino acids essential for tumour survival and expansion. Identifying this over-reliance on SHMT2 was akin to finding a critical choke point in the tumour’s energy supply chain.
The next step was to find a way to exploit this weakness. Fortuitously, the researchers identified sertraline, a common antidepressant widely used in clinical practice, as a potent inhibitor of SHMT2. This discovery was incredibly significant; repurposing an existing, FDA-approved drug meant bypassing years of costly and time-consuming drug development and safety trials. The strategy was clear: use sertraline to inhibit SHMT2, effectively cutting off the tumour’s access to a key energy source and hindering its ability to grow and spread.
The Avatar Host: Replicating the Tumour on a Chicken Egg
Identifying a potential drug candidate was only half the battle. The crucial next step was to test its efficacy against the patient’s unique tumour in a rapid and reliable manner, without further risk to the patient. This is where the second innovative component of their strategy came into play: the use of chicken egg avatars.
The team employed a cutting-edge method that involves carefully implanting a small piece of the patient’s tumour onto the chorioallantoic membrane (CAM) of a developing chicken embryo. The CAM, a highly vascularized extraembryonic membrane, provides an ideal, sterile, and nutrient-rich environment for human tumour fragments to grow and thrive. Within days, these tumour fragments establish a robust blood supply from the chicken embryo, effectively mimicking the microenvironment of the original tumour in the patient. This "avatar" host for the tumour offers a living, genetically identical replica of the patient’s cancer, providing an unparalleled platform for personalized drug testing.
"This technique speeds up the process of evaluating a treatment option in a way that simply wouldn’t be possible with traditional methods," emphasized Dr. Lim. "We could quickly confirm whether the drug we identified through proteomics could actually work for the patient’s tumour."
The advantages of this chicken egg avatar model are manifold. Unlike traditional cell culture models, which can lose key characteristics of the original tumour, the CAM model preserves the complex cellular architecture and heterogeneity of the patient’s tumour. Furthermore, it offers a significant time advantage over other in vivo models, such as patient-derived xenografts (PDX) in mice, which can take months to establish and test. The chicken egg avatars yield results in a matter of weeks, a critical factor when dealing with rapidly progressing cancers in vulnerable young patients. This accelerated timeline allows clinicians to make informed, personalized treatment decisions much faster than ever before.
The chicken egg avatars are part of the broader BRAvE initiative (Better Responses through Avatars and Evidence) at BCCHR, an ambitious program that seamlessly connects clinical care with cutting-edge research labs within the hospital. This integrated approach ensures that scientific discoveries are rapidly translated into tangible benefits for patients, fostering a dynamic ecosystem of innovation and patient-centered research.
A Multidisciplinary Consensus and Initial Encouraging Results
With a promising drug candidate (sertraline) identified through proteomics and its efficacy validated on the chicken egg avatar, the team presented their comprehensive findings to a panel of experts established by PROFYLE. This multidisciplinary panel, comprising oncologists, pathologists, geneticists, and pharmacologists from across Canada, rigorously reviewed the data. After careful consideration, and in the absence of other clear treatment pathways, the panel unanimously endorsed sertraline as the most promising treatment option for the patient at that critical juncture. This collaborative decision-making process, facilitated by the PROFYLE network, exemplifies the power of collective expertise in navigating complex therapeutic challenges.
Following the expert recommendation, the patient began treatment with sertraline. The results, while not a complete cure, were profoundly encouraging. The patient’s tumour growth significantly slowed, offering a much-needed reprieve and validating the innovative approach. This partial response meant that while additional treatment would still be needed, the personalized strategy had successfully halted the aggressive progression of a previously untreatable cancer, buying precious time and opening doors for subsequent therapies.
Dr. Rebecca Deyell, a pediatric oncologist and senior investigator involved in the study, highlighted the clinical significance. "For patients with rare and resistant cancers, every moment counts. To be able to offer a new, targeted therapy based on their tumour’s unique biology, especially when conventional options have failed, is a game-changer. This approach not only provides hope but also empowers us with data-driven decisions that were previously unimaginable."
Implications and the Road Ahead: A New Era for Pediatric Oncology
The success of this pan-Canadian effort heralds a new era in pediatric oncology, moving beyond the limitations of single-omic approaches and embracing a more holistic understanding of cancer biology. The integration of proteomics with rapid avatar testing represents a significant leap forward in personalized medicine, particularly for the most vulnerable patients.
"While there is more work to be done, this study shows that our approach can deliver personalized treatment recommendations fast enough to actually help patients with rare and difficult-to-treat cancers," stated Dr. Lange. "We now hope to expand this method to other children to identify effective treatments faster across the country."
The implications of this breakthrough are far-reaching:
-
A Complementary Paradigm: This research firmly establishes proteomics as an indispensable complement to genomics. While genomics identifies the "spelling mistakes" in the tumour’s DNA, proteomics reveals the "functional consequences" of those mistakes, directly pinpointing the proteins that are driving the cancer and are amenable to drug intervention. This multi-omic strategy offers a more complete picture of the tumour’s vulnerabilities.
-
Accelerated Drug Discovery and Repurposing: The ability to quickly identify and test existing, approved drugs for new indications (drug repurposing) is immensely powerful. It drastically reduces the time and cost associated with bringing new therapies to patients, offering a rapid pathway to clinical application for those with urgent needs.
-
Hope for Rare and Refractory Cancers: Pediatric cancers, by their very nature, are often rare, making it challenging to conduct large clinical trials and develop targeted therapies. This personalized approach offers a tailored solution for individual patients, providing options where none existed before. For children whose cancers resist standard treatments, this method offers a renewed sense of hope.
-
Scalability and National Impact: The collaborative framework of PROFYLE and ACCESS is crucial for scaling this innovative approach across Canada. By leveraging a national network of experts and resources, this method can potentially reach more children and young adults, ensuring equitable access to cutting-edge personalized care, regardless of their geographical location.
-
Future Research Directions: The success of this pilot study opens numerous avenues for future research. Efforts will focus on refining the proteomic analysis, exploring other novel drug targets, and optimizing the chicken egg avatar model for even greater predictive accuracy. Researchers will also investigate how to combine this approach with other emerging technologies, such as single-cell sequencing and advanced imaging, to gain an even deeper understanding of tumour biology. The ultimate goal is to conduct broader clinical trials to validate the efficacy of this combined approach across a larger cohort of pediatric cancer patients.
While the journey to a complete cure for pediatric cancer is ongoing, this pioneering work by the pan-Canadian team represents a monumental step forward. By deciphering the complex language of tumour proteins and leveraging the elegant simplicity of the chicken egg avatar, they have not only provided a tangible treatment option for a child in need but have also illuminated a promising new pathway toward a future where personalized, precise, and rapid cancer therapies are the standard of care for every young patient. The collaborative spirit and scientific ingenuity demonstrated in this study offer a powerful testament to the unwavering dedication of researchers committed to transforming outcomes for children battling cancer.
About the Author
